Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | FSHR | P23945 | 1/20 | 0.35 |
| ▸ | PRLHR | P49683 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769032 | 1.00 | EPHX2 (0.42) | EPHX2ALDH1A1HTTCARM1PRMT6 | |
| SCHEMBL12028129 | 1.00 | EPHX2 (0.42) | EPHX2ALDH1A1HTTCARM1PRMT6 | |
| SCHEMBL8151501 | 0.87 | P2RX3 (0.48) | EPHX2ALDH1A1CARM1PRMT6P2RX3 | |
| SCHEMBL8690915 | 0.87 | CTSC (0.48) | EPHX2ALDH1A1CTSCBACE1MAPT | |
| SCHEMBL15099494 | 0.87 | CTSC (0.48) | EPHX2ALDH1A1CTSCBACE1MAPT | |
| SCHEMBL8693462 | 0.87 | CTSC (0.48) | EPHX2ALDH1A1CTSCBACE1MAPT | |
| Hydrochloric Acid SCHEMBL7323379 | 0.86 | CTSC (0.47) | EPHX2ALDH1A1CTSCBACE1MAPT | |
| Hydrochloric Acid SCHEMBL3053757 | 0.86 | CTSC (0.47) | EPHX2ALDH1A1CTSCBACE1MAPT | |
| SCHEMBL13585574 | 0.85 | EPHX2 (0.42) | EPHX2ALDH1A1CARM1PRMT6MAPT | |
| SCHEMBL8228090 | 0.82 | CARM1 (0.40) | CARM1PRMT6CTSCMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710064-B2 | FOR THERAPY OF INFLAMMATORY OR IMMUNE DISEASES | BRISTOL-MYERS SQUIBB CO. | 2004-03-23 | — | — | US | disclosed |
| EP-1339718-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | Bristol-Myers Squibb Company (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
| WO-2002044181-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | HRH4, IL4I1, HRH2 | EPHX2 462/4885ALDH1A1 1272/4885HTT 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.